I was going to start a new thread, but as we are so far from...

I was going to start a new thread, but as we are so far from commercialisation, and we can expect very few ASX announcements, I will just put two charts here for now. They are from 16 May


And 1 July


We don't have dates on there as there is so much to do for the studies. It was mentioned though commercialisation by 2026, so we can assume they are referring to the breast and oral devices. The integration of pathology now will be part of all the systems, so that is what makes it so exciting but difficult to put a timeframe on everything.

Again, we are a long way off - recruitment, the studies, to FDA submission. But that is all happening concurrently with pathology and robotics.

Will we be cashflow positive in 2025? - no chance.

Does the company appear to have an extremely experienced team in place, with technology that could revolutionise cancer surgery and pathology in a few years, and a plan to execute? - it seems so.

Is a cash injection needed? - Definitely. Not a matter of if, but how and when. The latest quarterly I believe was 5 quarters. We can speculate - just to throw a suggestion up - late this calendar year, early next, if a trading range can be maintained in the 20s (if!!), then somewhere in the high teens/ early 20s.

Thoughts anyone?